Discovery of an Indole-Based p53-Y220C Reactivator with In Vivo Antitumor Activity via Structure-Guided Design
{{output}}
The oncogenic Y220C mutation destabilizes the p53 DNA-binding domain by creating a druggable surface crevice. Although the clinical advancement of PC14586 validates this target, the scarcity of structurally distinct correctors limits exploration of this chemic... ...
